X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2922) 2922
Publication (410) 410
Book Review (302) 302
Book Chapter (6) 6
Dissertation (4) 4
Conference Proceeding (3) 3
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2772) 2772
index medicus (2659) 2659
female (2539) 2539
breast cancer (1966) 1966
oncology (1563) 1563
triple negative breast neoplasms - pathology (1412) 1412
triple negative breast neoplasms - genetics (1400) 1400
cell line, tumor (1124) 1124
cancer (951) 951
middle aged (931) 931
triple negative breast neoplasms - metabolism (918) 918
animals (778) 778
adult (768) 768
prognosis (754) 754
triple negative breast neoplasms - drug therapy (722) 722
expression (688) 688
metastasis (684) 684
aged (657) 657
tumors (653) 653
triple-negative breast cancer (638) 638
gene expression (603) 603
gene expression regulation, neoplastic (592) 592
mice (587) 587
chemotherapy (557) 557
breast neoplasms - pathology (540) 540
breast neoplasms - genetics (485) 485
research (472) 472
genetic aspects (471) 471
analysis (461) 461
breast neoplasms - metabolism (431) 431
cell biology (426) 426
survival (424) 424
immunohistochemistry (419) 419
care and treatment (402) 402
apoptosis (396) 396
health aspects (394) 394
research article (351) 351
triple negative breast cancer (349) 349
article (344) 344
breast (343) 343
proteins (326) 326
mutation (325) 325
medical prognosis (320) 320
cells (318) 318
carcinoma (303) 303
cancer therapies (301) 301
signal transduction (301) 301
cell proliferation - drug effects (298) 298
receptor, erbb-2 - metabolism (296) 296
biomarkers, tumor - genetics (293) 293
medicine & public health (290) 290
xenograft model antitumor assays (289) 289
receptors, estrogen - metabolism (285) 285
cell proliferation (281) 281
development and progression (281) 281
medicine (276) 276
phenotype (276) 276
pathology (273) 273
neoplasm staging (262) 262
disease-free survival (258) 258
aged, 80 and over (257) 257
therapy (256) 256
antineoplastic agents - pharmacology (251) 251
multidisciplinary sciences (247) 247
triple negative breast neoplasms - mortality (245) 245
biochemistry & molecular biology (241) 241
subtypes (241) 241
estrogen (239) 239
breast neoplasms - drug therapy (234) 234
gene expression profiling (229) 229
receptors, progesterone - metabolism (227) 227
apoptosis - drug effects (226) 226
biomarkers, tumor - metabolism (224) 224
growth (223) 223
genes (220) 220
neoplasm metastasis (213) 213
mice, nude (211) 211
cancer research (210) 210
metastases (210) 210
receptor, erbb-2 - genetics (210) 210
mcf-7 cells (207) 207
identification (204) 204
kinases (204) 204
biomarkers (203) 203
antineoplastic agents - therapeutic use (201) 201
triple negative breast neoplasms - therapy (199) 199
risk factors (198) 198
skin and connective tissue diseases (198) 198
gene expression regulation, neoplastic - drug effects (197) 197
kaplan-meier estimate (197) 197
patients (196) 196
epidermal growth factor (195) 195
treatment outcome (193) 193
activation (190) 190
micrornas - genetics (186) 186
inhibition (183) 183
triple negative (180) 180
stem cells (179) 179
epithelial-mesenchymal transition (173) 173
estrogen-receptor (172) 172
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2908) 2908
Chinese (7) 7
French (4) 4
Spanish (3) 3
Polish (2) 2
Russian (2) 2
German (1) 1
Latvian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 4, pp. 304 - 311
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 508, Issue 1, pp. 103 - 107
Journal Article
Nature, ISSN 0028-0836, 01/2016, Volume 529, Issue 7586, pp. 413 - 417
Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain... 
SELECTIVE-INHIBITION | SUPER-ENHANCERS | RNA-SEQ | SUBTYPES | INFLAMMATION | STRATEGY | MULTIDISCIPLINARY SCIENCES | CELL IDENTITY | C-MYC | PP2A | LEUKEMIA | Chromatin - metabolism | Transcription, Genetic - drug effects | Humans | Transcription Factors - deficiency | Triple Negative Breast Neoplasms - drug therapy | Genome, Human - drug effects | Nuclear Proteins - deficiency | Protein Binding - drug effects | Triple Negative Breast Neoplasms - pathology | Female | Epigenesis, Genetic - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Nuclear Proteins - genetics | Triazoles - therapeutic use | Cell Proliferation - genetics | Mediator Complex Subunit 1 - metabolism | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Phosphoserine - metabolism | Genome, Human - genetics | Azepines - therapeutic use | Azepines - pharmacology | Binding, Competitive - drug effects | Transcription Factors - metabolism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Triple Negative Breast Neoplasms - genetics | Epigenesis, Genetic - genetics | Triple Negative Breast Neoplasms - metabolism | Nuclear Proteins - antagonists & inhibitors | Protein Phosphatase 2 - metabolism | Proteomics | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Chromatin - genetics | Casein Kinase II - metabolism | Drug Resistance, Neoplasm - drug effects | Protein Structure, Tertiary - drug effects | Antimitotic agents | Enzyme inhibitors | Patient outcomes | Breast cancer | Dosage and administration | Drug therapy | Antineoplastic agents | Studies | Inhibitor drugs | Drug resistance | Gene expression | Drug dosages | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 11/2013, Volume 13, Issue 1, pp. 537 - 537
Background: Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is an aggressive form of... 
Breast cancer | Microarray | Wnt | FFPE | Triple negative | GENE-EXPRESSION SIGNATURE | ANDROGEN RECEPTOR | REGULATES EXPRESSION | SUBTYPES | T-CELL-FACTOR | BETA-CATENIN | MESENCHYMAL TRANSITION | ONCOLOGY | PATHWAY | COLORECTAL-CANCER | BASAL | RNA, Small Interfering - genetics | Cell Proliferation | Prognosis | Follow-Up Studies | Oligonucleotide Array Sequence Analysis | Humans | Lung Neoplasms - metabolism | Gene Expression Regulation, Neoplastic | Bone Neoplasms - secondary | Gene Expression Profiling | Wnt Proteins - metabolism | Brain Neoplasms - metabolism | Immunoenzyme Techniques | Bone Neoplasms - metabolism | Neoplasm Recurrence, Local - pathology | Paraffin Embedding | Brain Neoplasms - secondary | Wnt Proteins - genetics | Lung Neoplasms - secondary | Triple Negative Breast Neoplasms - pathology | Biomarkers, Tumor - metabolism | Female | Bone Neoplasms - genetics | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Lung Neoplasms - genetics | Neoplasm Recurrence, Local - metabolism | Signal Transduction | RNA, Messenger - genetics | Brain Neoplasms - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | beta Catenin - metabolism | Blotting, Western | beta Catenin - genetics | Triple Negative Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - metabolism | beta Catenin - antagonists & inhibitors | Neoplasm Recurrence, Local - genetics | Biomarkers, Tumor - genetics | Neoplasm Staging | Cell Movement | Cohort Studies | Research | Metastasis | Biological markers | Analysis | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Journal Article
Nature Communications, ISSN 2041-1723, 05/2017, Volume 8, Issue 1, pp. 15081 - 15081
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 6, pp. e0157368 - e0157368
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling.... 
TUMOR-INFILTRATING LYMPHOCYTES | SURVIVAL | WOMEN | RATES | IXABEPILONE | MULTIDISCIPLINARY SCIENCES | IDENTIFICATION | PROGNOSTIC VALUE | EXPRESSION | PATHOLOGICAL COMPLETE RESPONSE | PACLITAXEL | Immunohistochemistry | Stromal Cells - pathology | Humans | Laser Capture Microdissection | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Neoplasm Proteins - metabolism | Triple Negative Breast Neoplasms - drug therapy | Triple Negative Breast Neoplasms - classification | Neoplasm Grading | Microarray Analysis | Stromal Cells - drug effects | Female | Retrospective Studies | Neoplasm Proteins - genetics | Gene Expression | Datasets as Topic | Computational Biology | Antineoplastic Combined Chemotherapy Protocols | Triple Negative Breast Neoplasms - mortality | Lymphocytes, Tumor-Infiltrating - drug effects | Disease Progression | Triple Negative Breast Neoplasms - genetics | Lymphocytes, Tumor-Infiltrating - pathology | Neoadjuvant Therapy - methods | Survival Analysis | Mesenchyme | Clinical trials | Oncology | Biochemistry | Metastasis | Datasets | Confidence intervals | Signal transduction | Histopathology | Epidermal growth factor | Lymphocytes | Cell cycle | Bone marrow | Bioindicators | Pretreatment | Medical research | BRCA1 protein | Immunomodulation | Breast cancer | Gene expression | Patients | Androgens | Chemotherapy | Biopsy | Stromal cells | Biomarkers | Breast | Cancer | Tumors | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2016, Volume 22, Issue 15, pp. 3764 - 3773
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2015, Volume 33, Issue 17, pp. 1902 - 1909
Journal Article